Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315865845> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4315865845 abstract "Bevacizumab and eribulin are novel agents for the treatment of HER2‑negative metastatic breast cancer (MBC); however, the choice between bevacizumab and eribulin for MBC can be difficult. The present study aimed to compare two treatment strategies, eribulin followed by bevacizumab and paclitaxel (BEV + PTX) versus BEV + PTX followed by eribulin, to determine whether the order of administration affects the outcome of MBC in the real world. A total of 180 patients who started BEV + PTX and eribulin treatment for HER2‑negative MBC from August 2011 to June 2018 were selected. Of these, 84 patients were treated with both BEV + PTX and eribulin sequentially. To evaluate the influence of the sequential order, the efficacy of BEV + PTX followed by eribulin (B‑E arm) was compared to treatment with the reverse sequence (E‑B arm). The propensity score matching method (PSMA) was used to improve the robustness of the findings from the present study. A total of 60 cases analyzed received BEV + PTX or eribulin as either first‑ or second‑line treatment. In the entire cohort, the median time to failure of strategy (TFS) was 16.8 and 9.9 months in the B‑E and E‑B arms, respectively [hazard ratio (HR)=0.515, 95% CI 0.298‑0.889, P=0.017). A similar HR was derived from PSMA for TFS. Using PSMA, TFS was 16.9 and 9.9 months in the B‑E and E‑B arms, respectively (HR=0.491, 95% CI 0.253‑0.952, P=0.031). These results suggested that when both bevacizumab and eribulin are administered, bevacizumab should be administered first and eribulin should be administered later to ensure the most effective use of each drug." @default.
- W4315865845 created "2023-01-13" @default.
- W4315865845 creator A5016763283 @default.
- W4315865845 creator A5019142438 @default.
- W4315865845 creator A5024749177 @default.
- W4315865845 creator A5026695277 @default.
- W4315865845 creator A5028379172 @default.
- W4315865845 creator A5047606517 @default.
- W4315865845 creator A5050792958 @default.
- W4315865845 creator A5068270834 @default.
- W4315865845 creator A5071117344 @default.
- W4315865845 creator A5073567252 @default.
- W4315865845 date "2023-01-13" @default.
- W4315865845 modified "2023-09-30" @default.
- W4315865845 title "Real‑world effect of bevacizumab and eribulin on metastatic breast cancer using a propensity score matching analysis" @default.
- W4315865845 cites W1616017667 @default.
- W4315865845 cites W1981535076 @default.
- W4315865845 cites W2007679672 @default.
- W4315865845 cites W2039906674 @default.
- W4315865845 cites W2074890479 @default.
- W4315865845 cites W2075610273 @default.
- W4315865845 cites W2086809350 @default.
- W4315865845 cites W2095832858 @default.
- W4315865845 cites W2100669312 @default.
- W4315865845 cites W2103563357 @default.
- W4315865845 cites W2126275851 @default.
- W4315865845 cites W2127152525 @default.
- W4315865845 cites W2137545466 @default.
- W4315865845 cites W2142915226 @default.
- W4315865845 cites W2143481677 @default.
- W4315865845 cites W2145835533 @default.
- W4315865845 cites W2151782847 @default.
- W4315865845 cites W2153982924 @default.
- W4315865845 cites W2157769714 @default.
- W4315865845 cites W2167224460 @default.
- W4315865845 cites W2346198182 @default.
- W4315865845 cites W2503449349 @default.
- W4315865845 doi "https://doi.org/10.3892/mco.2023.2608" @default.
- W4315865845 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36761387" @default.
- W4315865845 hasPublicationYear "2023" @default.
- W4315865845 type Work @default.
- W4315865845 citedByCount "0" @default.
- W4315865845 crossrefType "journal-article" @default.
- W4315865845 hasAuthorship W4315865845A5016763283 @default.
- W4315865845 hasAuthorship W4315865845A5019142438 @default.
- W4315865845 hasAuthorship W4315865845A5024749177 @default.
- W4315865845 hasAuthorship W4315865845A5026695277 @default.
- W4315865845 hasAuthorship W4315865845A5028379172 @default.
- W4315865845 hasAuthorship W4315865845A5047606517 @default.
- W4315865845 hasAuthorship W4315865845A5050792958 @default.
- W4315865845 hasAuthorship W4315865845A5068270834 @default.
- W4315865845 hasAuthorship W4315865845A5071117344 @default.
- W4315865845 hasAuthorship W4315865845A5073567252 @default.
- W4315865845 hasBestOaLocation W43158658451 @default.
- W4315865845 hasConcept C121608353 @default.
- W4315865845 hasConcept C126322002 @default.
- W4315865845 hasConcept C143998085 @default.
- W4315865845 hasConcept C17923572 @default.
- W4315865845 hasConcept C207103383 @default.
- W4315865845 hasConcept C2775930923 @default.
- W4315865845 hasConcept C2776387010 @default.
- W4315865845 hasConcept C2776694085 @default.
- W4315865845 hasConcept C2777292972 @default.
- W4315865845 hasConcept C2777802072 @default.
- W4315865845 hasConcept C44249647 @default.
- W4315865845 hasConcept C530470458 @default.
- W4315865845 hasConcept C71924100 @default.
- W4315865845 hasConceptScore W4315865845C121608353 @default.
- W4315865845 hasConceptScore W4315865845C126322002 @default.
- W4315865845 hasConceptScore W4315865845C143998085 @default.
- W4315865845 hasConceptScore W4315865845C17923572 @default.
- W4315865845 hasConceptScore W4315865845C207103383 @default.
- W4315865845 hasConceptScore W4315865845C2775930923 @default.
- W4315865845 hasConceptScore W4315865845C2776387010 @default.
- W4315865845 hasConceptScore W4315865845C2776694085 @default.
- W4315865845 hasConceptScore W4315865845C2777292972 @default.
- W4315865845 hasConceptScore W4315865845C2777802072 @default.
- W4315865845 hasConceptScore W4315865845C44249647 @default.
- W4315865845 hasConceptScore W4315865845C530470458 @default.
- W4315865845 hasConceptScore W4315865845C71924100 @default.
- W4315865845 hasIssue "2" @default.
- W4315865845 hasLocation W43158658451 @default.
- W4315865845 hasLocation W43158658452 @default.
- W4315865845 hasLocation W43158658453 @default.
- W4315865845 hasOpenAccess W4315865845 @default.
- W4315865845 hasPrimaryLocation W43158658451 @default.
- W4315865845 hasRelatedWork W2033027303 @default.
- W4315865845 hasRelatedWork W2035195370 @default.
- W4315865845 hasRelatedWork W2037317309 @default.
- W4315865845 hasRelatedWork W2077649377 @default.
- W4315865845 hasRelatedWork W2091442233 @default.
- W4315865845 hasRelatedWork W2126275851 @default.
- W4315865845 hasRelatedWork W3089750310 @default.
- W4315865845 hasRelatedWork W3133405547 @default.
- W4315865845 hasRelatedWork W4240591557 @default.
- W4315865845 hasRelatedWork W4247339171 @default.
- W4315865845 hasVolume "18" @default.
- W4315865845 isParatext "false" @default.
- W4315865845 isRetracted "false" @default.
- W4315865845 workType "article" @default.